AstraZeneca achieves $30.7B in six-month sales
AstraZeneca achieved total revenues of $30.7 billion during the first half of 2026, a 6% increase compared to the same period last year. This growth is attributed to rising demand for cancer medications, especially in the oncology and rare disease sectors. The oncology segment's revenue increased by 15%, reaching $14.12 billion, driven by higher demand for drugs such as Tagrisso and Imfinzi. The majority of sales are dependent on the U.S. market. Additionally, revenues from the rare disease sector grew by 11%, accounting for 16% of total sales. The company expects overall revenues to rise between 5% and 9% for the entire year.
articleDetails.fontSize.sizeحجم النص
تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي
comments.heading